Pharmaceuticals
These 4 charts show the scale of Novo Nordisk’s woes
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company. But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago. Pricing pressure, fierce competition, and pipeline setbacks have […]
Read More
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027, […]
Read More
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial
Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target. The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning. Eli Lilly‘s stock […]
Read More
With Trump’s ‘reciprocal’ tariffs struck down, here are the industries still facing higher rates
The Supreme Court during a rain storm in Washington, Feb. 20, 2026. Annabelle Gordon | Bloomberg | Getty Images The Supreme Court on Friday ruled that President Donald Trump’s country-specific “reciprocal” tariffs are unconstitutional, delivering a win for many consumer companies facing higher import costs. But the ruling doesn’t cover all sectors. The Supreme Court […]
Read More
FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals
Food and Drug Administration Commissioner Marty Makary warned that the U.S. is falling behind China in early-stage drug development and called for reforms that could streamline the process for starting trials on new treatments. In an interview with CNBC on Wednesday, Makary specifically pointed to three bottlenecks that he said cause the U.S. to fall […]
Read More
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal
A researcher works in the lab at the Moderna headquarters in Cambridge, Massachusetts, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna said on Wednesday the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing the agency’s earlier decision to refuse to accept the application in a move […]
Read More
FDA chief Marty Makary says ‘everything should be over the counter’ unless drug is unsafe or addictive
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter” unless a drug is unsafe, addictive or requires monitoring – doubling down on a push that some in the pharmaceutical industry have questioned. In an interview Wednesday in Washington, D.C., Makary said the FDA aims to make […]
Read More
Prices, pipelines and patent cliffs: Inside pharma’s big reset
This earnings season, Europe’s biggest pharma companies posted results ranging from 7% beats to 3% misses — but no one really cared. Instead, drugmakers looked ahead, with 2026 shaping up to be a defining year following a dramatic 2025, and one where the impact from last year’s developments is set to crystallize. “2025 was about […]
Read More
Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant
Paul Hudson, CEO Sanofi, speaking on CNBC’s Squawk Box at the World Economic Forum Annual Meeting in Davos, Switzerland on Jan. 18th, 2024. Adam Galici | CNBC French drugmaker Sanofi ousted CEO Paul Hudson on Thursday, ending a six-year tenure marked by a stalled drive to replace blockbuster drugs going off patent and rising pressure from […]
Read More
Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight loss drugs at the White House, Nov. 6, 2025. Andrew Caballero-Reynolds | Afp | Getty Images Novo Nordisk entered 2026 with the momentum of a historic year in more ways than one — but recent weeks have delivered more […]
Read More